iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)

PHASE3CompletedINTERVENTIONAL
Enrollment

582

Participants

Timeline

Start Date

July 7, 2022

Primary Completion Date

October 20, 2023

Study Completion Date

October 20, 2023

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Insulin glargine/Lixisenatide

solution, by subcutaneous injection

DRUG

IDegAsp

solution, by subcutaneous injection

DRUG

Metformin

Tablet, orally

DRUG

SGLT2 inhibitor

Tablet, orally

Trial Locations (60)

100853

Investigational Site Number : 1560001, Beijing

101200

Investigational Site Number : 1560027, Beijing

110004

Investigational Site Number : 1560009, Shenyang

116011

Investigational Site Number : 1560053, Dalian

130000

Investigational Site Number : 1560047, Tonghua

130021

Investigational Site Number : 1560059, Changchun

130041

Investigational Site Number : 1560046, Changchun

150001

Investigational Site Number : 1560045, Harbin

200040

Investigational Site Number : 1560003, Shanghai

Investigational Site Number : 1560020, Shanghai

201700

Investigational Site Number : 1560007, Shanghai

210011

Investigational Site Number : 1560028, Nanjing

212001

Investigational Site Number : 1560034, Zhenjiang

222002

Investigational Site Number : 1560060, Lianyungang

223300

Investigational Site Number : 1560056, Huai'an

226001

Investigational Site Number : 1560057, Nantong

250012

Investigational Site Number : 1560040, Jinan

250013

Investigational Site Number : 1560014, Jinan

266042

Investigational Site Number : 1560048, Qingdao

300052

Investigational Site Number : 1560016, Tianjin

300121

Investigational Site Number : 1560013, Tianjin

310014

Investigational Site Number : 1560010, Hangzhou

337055

Investigational Site Number : 1560037, Pingxiang

400010

Investigational Site Number : 1560044, Chongqing

410013

Investigational Site Number : 1560011, Changsha

412007

Investigational Site Number : 1560005, Zhuzhou

414000

Investigational Site Number : 1560033, Yueyang

415000

Investigational Site Number : 1560052, Changde

434020

Investigational Site Number : 1560058, Jingzhou

435000

Investigational Site Number : 1560055, Huangshi

438000

Investigational Site Number : 1560035, Huanggang

471003

Investigational Site Number : 1560031, Luoyang

510080

Investigational Site Number : 1560043, Guangzhou

510150

Investigational Site Number : 1560029, Guangzhou

516001

Investigational Site Number : 1560022, Huizhou

528399

Investigational Site Number : 1560030, Foshan

610081

Investigational Site Number : 1560054, Chengdu

611130

Investigational Site Number : 1560024, Chengdu

643002

Investigational Site Number : 1560002, Zigong

730000

Investigational Site Number : 1560039, Lanzhou

014010

Investigational Site Number : 1560008, Baotou

Unknown

Investigational Site Number : 1560019, Beijing

Investigational Site Number : 1560004, Chenzhou

Investigational Site Number : 1560025, Harbin

Investigational Site Number : 1560038, Hohhot

Investigational Site Number : 1560051, Huzhou

Investigational Site Number : 1560041, Kaifeng

Investigational Site Number : 1560017, Nanjing

Investigational Site Number : 1560018, Nanjing

Investigational Site Number : 1560012, Qinhuangdao

Investigational Site Number : 1560006, Shanghai

Investigational Site Number : 1560050, Suzhou

Investigational Site Number : 1560015, Xuzhou

Investigational Site Number : 1560032, Yueyang

Investigational Site Number : 1560049, Zhengzhou

Investigational Site Number : 1560036, Zhongshan

061000

Investigational Site Number : 1560023, Cangzhou

056002

Investigational Site Number : 1560021, Handan

054031

Investigational Site Number : 1560042, Xingtai

044000

Investigational Site Number : 1560026, Yuncheng

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY